KPTI (Karyopharm Therapeutics Inc.) רווח למניה בארבעת הרבעונים האחרונים

Karyopharm Therapeutics (KPTI) maintains a stable position thanks to Xpovio, although patent expirations and new competition are eroding its market advantages. High sales margins are offset by promotion costs and the development of new products, which impacts free cash flow, currently standing at 11.80. This EPS (TTM) chart, which clearly demonstrates pricing changes, reveals the profit dynamics. Meanwhile, the automation of substance synthesis is supplemented by mandatory medical supervision of clinical trials.
Karyopharm - פילוחים אנליטיים ומדדי מפתח (KPTI)

This indicator reflects the percentage change in trailing twelve-month (TTM) earnings per share over a year, capturing the sensitivity of the bottom line to operating expenses and revenue. For Karyopharm Therapeutics (KPTI), whose success depends on its R&D pipeline and capital burn rate control, measuring the annual EPS TTM growth allows for an assessment of resource management efficiency before the company achieves stable commercial profitability.